Thyroid transcription factor-1 immunostaining in World Health Organization type AB thymoma

2015 ◽  
Vol 68 (4) ◽  
pp. 618-619 ◽  
Author(s):  
Todd Smith ◽  
Francesco Mauri ◽  
Kikkeri N Naresh
Keyword(s):  
Transcription Factor ◽  
World Health Organization ◽  
World Health ◽  
Thyroid Transcription Factor 1 ◽  
Thyroid Transcription Factor ◽  
Health Organization ◽  
Type Ab ◽  
Transcription Factor 1 ◽  
Type Ab Thymoma

Immunohistochemical Analysis of Lung Carcinomas With Pure or Partial Bronchioloalveolar Differentiation

2004 ◽  
Vol 128 (4) ◽  
pp. 406-414
Author(s):  
G. Peter Sarantopoulos ◽  
Dorina Gui ◽  
Peter Shintaku ◽  
Longshen Hong ◽  
Ya-Ying Wang ◽  
...  
Keyword(s):  
Transcription Factor ◽  
World Health Organization ◽  
Immunohistochemical Staining ◽  
World Health ◽  
Cytokeratin 20 ◽  
Cytokeratin 7 ◽  
Thyroid Transcription Factor 1 ◽  
Thyroid Transcription Factor ◽  
Health Organization ◽  
Transcription Factor 1

Abstract Context.—In 1999, the World Health Organization redefined bronchioloalveolar carcinomas (BACs) as those neoplasms with only a pure lepidic growth pattern and no invasion. Objectives.—The present study examined 45 lung cancers with a BAC component (1) to determine whether these tumors would be classified as BACs by current World Health Organization standards, (2) to quantitate the BAC component within these tumors, and (3) to see if phenotypic differences exist between the so-called invasive and noninvasive regions of these tumors. Design.—Retrospective review of hematoxylin-eosin–stained slides and classification of histologic grade, tumor subtype, and percentage of pure BAC pattern, with further characterization by immunohistochemical staining for thyroid transcription factor 1, cytokeratin 7, cytokeratin 20, and Ki-67 antibodies. Results.—Only 7 (15.6%) of the 45 tumors examined could be classified as BAC by current strict World Health Organization criteria. Those tumors, classified as nonmucinous and mixed, showed similar immunohistochemical staining for cytokeratin 7, cytokeratin 20, and thyroid transcription factor 1; mucinous tumors showed disparate staining. Significant differences in immunohistochemical staining and tumor cell proliferation were seen for the regions of tumors designated as lepidic, infiltrative, and leading edge and for the regions of tumors with different histologic grades (ie, well, moderately, and poorly differentiated). Conclusions.—Nonmucinous and mixed BACs are phenotypically similar and show identical immunohistochemical staining patterns; mucinous tumors, on the other hand, show disparate immunohistochemical staining. Pulmonary neoplasms designated as adenocarcinomas with a BAC component represent a heterogenous group with a range of cell types, differentiation, growth, and immunophenotypes. Within an individual neoplasm, there are regional differences in these parameters as well.

scholarly journals Identification of Thyroid Transcription Factor-1 in C Cells and Parathyroid Cells

Endocrinology ◽  
1998 ◽  
Vol 139 (6) ◽  
pp. 3014-3017 ◽  
Author(s):  
Koichi Suzuki ◽  
Yoshihiko Kobayashi ◽  
Ryohei Katoh ◽  
Leonard D. Kohn ◽  
Akira Kawaoi
Keyword(s):  
Transcription Factor ◽  
C Cells ◽  
Thyroid Transcription Factor 1 ◽  
Thyroid Transcription Factor ◽  
Transcription Factor 1

Thyroid transcription factor-1 expression in colorectal adenocarcinomas

2011 ◽  
Vol 207 (11) ◽  
pp. 686-690 ◽  
Author(s):  
Matthias Dettmer ◽  
Tae Eun Kim ◽  
Chan Kwon Jung ◽  
Eun Sun Jung ◽  
Kyo Young Lee ◽  
...  
Keyword(s):  
Transcription Factor ◽  
Thyroid Transcription Factor 1 ◽  
Thyroid Transcription Factor ◽  
Transcription Factor 1 ◽  
Colorectal Adenocarcinomas

Thyroid Transcription Factor 1 Immunohistochemistry as an Intraoperative Diagnostic Tool at Frozen Section for Distinction Between Primary and Secondary Lung Tumors

2007 ◽  
Vol 131 (4) ◽  
pp. 582-587
Author(s):  
David N. Butcher ◽  
Peter Goldstraw ◽  
George Ladas ◽  
Michael E. Dusmet ◽  
Mary N. Sheppard ◽  
...  
Keyword(s):  
Transcription Factor ◽  
Frozen Section ◽  
Operative Procedure ◽  
Tumor Type ◽  
Diagnostic Confidence ◽  
Thyroid Transcription Factor 1 ◽  
Specificity And Sensitivity ◽  
Thyroid Transcription Factor ◽  
Transcription Factor 1 ◽  
Pulmonary Tumors

Abstract Context.—Intraoperative distinction between primary and metastatic carcinomas in the lung at frozen section remains problematic. Objective.—To assess the value and practicality of immunohistochemistry for thyroid transcription factor 1 at the time of intraoperative frozen section. Design.—Thirty-three patients presented with either a solitary pulmonary mass or 2 pulmonary masses and a history of carcinoma in a different organ. In addition to routine frozen section for assessment of tumor type, we looked for expression of thyroid transcription factor 1, using the EnVision system with abridged methodology. Results.—Ten cases were positive for thyroid transcription factor 1, which was confirmed on subsequent paraffin sections. Nine of these were confirmed as primary pulmonary adenocarcinomas, but 1 case proved to be a rare false-positive metastatic colonic carcinoma. Twenty-three cases were negative on frozen section and reported as favoring metastatic disease. In all cases, additional immunohistochemical data increased diagnostic confidence, but particularly in cases of positive primary pulmonary tumors and in cases with disease metastatic from sites other than the large bowel. The average time in addition to that of the basic frozen section was 24 minutes per test with a cost of £32 (US$57). Conclusions.—Frozen section immunohistochemistry for thyroid transcription factor 1 shows specificity and sensitivity similar to those seen for formalin-fixed tissues and is feasible within the time frame of a thoracotomy. Diagnostic confidence is increased, especially with positive primary pulmonary tumors. However, its practice should be properly planned within an operative procedure as liberal usage will likely have significant staff and cost implications.

scholarly journals Prognostic Value of Thyroid Transcription Factor-1 Expression in Patients with Advanced Lung Adenocarcinoma

In Vivo ◽  
2018 ◽  
Vol 32 (6) ◽  
pp. 1571-1579 ◽  
Author(s):  
ROLANDAS ZABLOCKIS ◽  
EDVARDAS ŽURAUSKAS ◽  
EDVARDAS DANILA ◽  
VYGANTAS GRUSLYS
Keyword(s):  
Transcription Factor ◽  
Lung Adenocarcinoma ◽  
Prognostic Value ◽  
Thyroid Transcription Factor 1 ◽  
Thyroid Transcription Factor ◽  
Transcription Factor 1
Sign in / Sign up

Export Citation Format

Share Document